Recent News

• 06.11.2026 - Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
• 03.04.2026 - Harmony Biosciences to Participate in Upcoming Investor Conferences
• 02.24.2026 - Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
• 02.17.2026 - Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
• 02.10.2026 - Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
• 01.12.2026 - Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
• 01.07.2026 - Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 12.08.2025 - Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
• 12.02.2025 - Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
• 11.24.2025 - Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

Recent Filings

• 06.09.2026 - 144 Report of proposed sale of securities
• 06.05.2026 - 144 Report of proposed sale of securities
• 06.04.2026 - 144 Report of proposed sale of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 3 Initial statement of beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities